Which has stronger valuation and earnings, LQDA or PLSE?

Liquidia has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 43.91 -$68.92M $0.14 558.36 Pulse Biosciences $350K 5,625.78 -$72.78M -$1.10 N/A

Do analysts rate STVN or PLSE?

Pulse Biosciences has a consensus target price of $30.67, indicating a potential upside of 7.79%. Given Pulse Biosciences' higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00 Pulse Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Pulse Biosciences (PLSE) Competitors

$28.45 +0.95 (+3.45%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$28.52 +0.07 (+0.23%)

As of 06/26/2026 07:19 PM Eastern

Compare

PLSE vs. LQDA, BLCO, STVN, LIVN, and NVST

Should you buy Pulse Biosciences stock or one of its competitors? MarketBeat compares Pulse Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulse Biosciences include Liquidia (LQDA), Bausch + Lomb (BLCO), Stevanato Group (STVN), LivaNova (LIVN), and Envista (NVST). These companies are all part of the "medical equipment" industry.

How does Pulse Biosciences compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Liquidia has a net margin of 7.74% compared to Pulse Biosciences' net margin of 0.00%. Liquidia's return on equity of 46.82% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Pulse Biosciences	N/A	-86.67%	-73.61%

Liquidia presently has a consensus price target of $67.43, suggesting a potential downside of 13.74%. Pulse Biosciences has a consensus price target of $30.67, suggesting a potential upside of 7.79%. Given Pulse Biosciences' higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.90
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Liquidia had 10 more articles in the media than Pulse Biosciences. MarketBeat recorded 11 mentions for Liquidia and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.89 beat Liquidia's score of 0.32 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Liquidia	Neutral
Pulse Biosciences	Very Positive

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Liquidia has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Liquidia has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	43.91	-$68.92M	$0.14	558.36
Pulse Biosciences	$350K	5,625.78	-$72.78M	-$1.10	N/A

Summary

Liquidia beats Pulse Biosciences on 11 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Bausch + Lomb?

Pulse Biosciences (NASDAQ:PLSE) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Pulse Biosciences presently has a consensus price target of $30.67, indicating a potential upside of 7.79%. Bausch + Lomb has a consensus price target of $17.92, indicating a potential upside of 9.97%. Given Bausch + Lomb's higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pulse Biosciences has a net margin of 0.00% compared to Bausch + Lomb's net margin of -4.21%. Bausch + Lomb's return on equity of 3.60% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Bausch + Lomb	-4.21%	3.60%	1.69%

Pulse Biosciences has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

In the previous week, Pulse Biosciences had 1 more articles in the media than Bausch + Lomb. MarketBeat recorded 1 mentions for Pulse Biosciences and 0 mentions for Bausch + Lomb. Pulse Biosciences' average media sentiment score of 1.89 beat Bausch + Lomb's score of 0.00 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Pulse Biosciences	Very Positive
Bausch + Lomb	Neutral

Pulse Biosciences has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	5,625.78	-$72.78M	-$1.10	N/A
Bausch + Lomb	$5.21B	1.12	-$360M	-$0.62	N/A

Summary

Pulse Biosciences beats Bausch + Lomb on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Stevanato Group has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.20B	4.48	€158.21M	€0.59	30.15
Pulse Biosciences	$350K	5,625.78	-$72.78M	-$1.10	N/A

Stevanato Group has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

Pulse Biosciences has a consensus target price of $30.67, indicating a potential upside of 7.79%. Given Pulse Biosciences' higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Stevanato Group has a net margin of 11.76% compared to Pulse Biosciences' net margin of 0.00%. Stevanato Group's return on equity of 10.27% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
Pulse Biosciences	N/A	-86.67%	-73.61%

77.0% of Pulse Biosciences shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Stevanato Group had 5 more articles in the media than Pulse Biosciences. MarketBeat recorded 6 mentions for Stevanato Group and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.89 beat Stevanato Group's score of -0.80 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Stevanato Group	Negative
Pulse Biosciences	Very Positive

Summary

Stevanato Group beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

LivaNova has a net margin of 7.48% compared to Pulse Biosciences' net margin of 0.00%. LivaNova's return on equity of 16.48% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Pulse Biosciences	N/A	-86.67%	-73.61%

In the previous week, LivaNova had 2 more articles in the media than Pulse Biosciences. MarketBeat recorded 3 mentions for LivaNova and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.89 beat LivaNova's score of 0.93 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
LivaNova	Positive
Pulse Biosciences	Very Positive

LivaNova has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

Pulse Biosciences has lower revenue, but higher earnings than LivaNova. Pulse Biosciences is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.30	-$242.47M	$1.95	42.76
Pulse Biosciences	$350K	5,625.78	-$72.78M	-$1.10	N/A

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

LivaNova presently has a consensus price target of $80.75, indicating a potential downside of 3.16%. Pulse Biosciences has a consensus price target of $30.67, indicating a potential upside of 7.79%. Given Pulse Biosciences' higher possible upside, analysts plainly believe Pulse Biosciences is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

LivaNova beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Envista?

Pulse Biosciences (NASDAQ:PLSE) and Envista (NYSE:NVST) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, Pulse Biosciences had 1 more articles in the media than Envista. MarketBeat recorded 1 mentions for Pulse Biosciences and 0 mentions for Envista. Pulse Biosciences' average media sentiment score of 1.89 beat Envista's score of 0.83 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Pulse Biosciences	Very Positive
Envista	Positive

Pulse Biosciences presently has a consensus price target of $30.67, indicating a potential upside of 7.79%. Envista has a consensus price target of $28.67, indicating a potential upside of 6.29%. Given Pulse Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Pulse Biosciences is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Envista has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	5,625.78	-$72.78M	-$1.10	N/A
Envista	$2.72B	1.61	$47M	$0.41	65.78

77.0% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 1.0% of Envista shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Envista has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Envista has a net margin of 2.41% compared to Pulse Biosciences' net margin of 0.00%. Envista's return on equity of 7.11% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Envista	2.41%	7.11%	3.91%

Summary

Pulse Biosciences and Envista tied by winning 8 of the 16 factors compared between the two stocks.

Get Pulse Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLSE vs. The Competition

Export

Metric	Pulse Biosciences	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.90B	$7.37B	$6.70B	$12.22B
Dividend Yield	N/A	1.26%	2.67%	6.13%
P/E Ratio	-25.86	51.24	25.84	24.18
Price / Sales	5,625.78	93.05	576.85	114.69
Price / Cash	N/A	25.94	46.99	54.37
Price / Book	23.91	7.56	10.78	6.36
Net Income	-$72.78M	$159.20M	$3.58B	$337.99M
7 Day Performance	11.13%	1.80%	2.22%	0.10%
1 Month Performance	15.09%	0.05%	1.11%	-0.11%
1 Year Performance	88.66%	5.96%	34.28%	27.60%

Pulse Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLSE Pulse Biosciences	2.6661 of 5 stars	$28.45 +3.5%	$30.67 +7.8%	+91.1%	$1.90B	$350K	N/A	140	Positive News Gap Down High Trading Volume
LQDA Liquidia	2.8071 of 5 stars	$74.04 -1.9%	$67.43 -8.9%	+509.3%	$6.71B	$158.32M	528.89	50	Analyst Downgrade Insider Trade
BLCO Bausch + Lomb	2.6595 of 5 stars	$15.25 +2.1%	$17.92 +17.5%	+35.0%	$5.33B	$5.10B	N/A	13,000
STVN Stevanato Group	2.9204 of 5 stars	€16.79 -0.9%	N/A	-29.5%	€5.08B	€1.34B	28.46	6,010
LIVN LivaNova	1.5821 of 5 stars	$78.68 0.0%	$80.75 +2.6%	+82.1%	$4.32B	$1.39B	40.35	3,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLSE) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulse Biosciences (PLSE) Competitors

PLSE vs. LQDA, BLCO, STVN, LIVN, and NVST

How does Pulse Biosciences compare to Liquidia?

Summary

How does Pulse Biosciences compare to Bausch + Lomb?

Summary

How does Pulse Biosciences compare to Stevanato Group?

Summary

How does Pulse Biosciences compare to LivaNova?

Summary

How does Pulse Biosciences compare to Envista?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulse Biosciences (PLSE) Competitors

PLSE vs. LQDA, BLCO, STVN, LIVN, and NVST

How does Pulse Biosciences compare to Liquidia?

Is LQDA or PLSE more profitable?

Do analysts recommend LQDA or PLSE?

Does the media refer more to LQDA or PLSE?

Do institutionals and insiders have more ownership in LQDA or PLSE?

Which has more risk and volatility, LQDA or PLSE?

Which has stronger valuation and earnings, LQDA or PLSE?

Summary

How does Pulse Biosciences compare to Bausch + Lomb?

Do analysts rate PLSE or BLCO?

Do insiders & institutionals believe in PLSE or BLCO?

Is PLSE or BLCO more profitable?

Which has more risk and volatility, PLSE or BLCO?

Does the media favor PLSE or BLCO?

Which has stronger earnings & valuation, PLSE or BLCO?

Summary

How does Pulse Biosciences compare to Stevanato Group?

Which has higher valuation & earnings, STVN or PLSE?

Which has more volatility and risk, STVN or PLSE?

Do analysts rate STVN or PLSE?

Is STVN or PLSE more profitable?

Do insiders and institutionals believe in STVN or PLSE?

Does the media refer more to STVN or PLSE?

Summary

How does Pulse Biosciences compare to LivaNova?

Is LIVN or PLSE more profitable?

Does the media refer more to LIVN or PLSE?

Which has more volatility & risk, LIVN or PLSE?

Which has preferable valuation and earnings, LIVN or PLSE?

Do institutionals & insiders believe in LIVN or PLSE?

Do analysts rate LIVN or PLSE?

Summary

How does Pulse Biosciences compare to Envista?

Does the media favor PLSE or NVST?

Do analysts recommend PLSE or NVST?

Which has higher valuation and earnings, PLSE or NVST?

Do institutionals and insiders hold more shares of PLSE or NVST?

Which has more risk and volatility, PLSE or NVST?

Is PLSE or NVST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools